Takeda Gets CHMP Approval for Recombinant ADAMTS13
By Chris Wack
Takeda said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval, under exceptional circumstances, of recombinant ADAMTS13 for the treatment of ADAMTS13 deficiency in children and adult patients with congenital thrombotic thrombocytopenic purpura.
The European Commission will consider the CHMP positive opinion when determining the potential marketing authorization for rADAMTS13 throughout the European Union.
If approved, Takeda said, rADAMTS13 will be the first and only enzyme replacement therapy in the EU for the treatment of cTTP.
Congenital thrombotic thrombocytopenic purpura is an ultra-rare, chronic blood clotting disorder caused by a deficiency in the ADAMTS13 enzyme.
The committee's positive opinion was supported by the totality of evidence including the interim analysis of efficacy, pharmacokinetic, safety and tolerability data from a Phase 3 trial.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
May 31, 2024 10:26 ET (14:26 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks